Cargando...
Can an immune checkpoint inhibitor (sometimes) make things worse?
Champiat and colleagues suggest that a small subset of patients on PD1/PDL1 inhibitors at their center appear to exhibit hyperprogression of disease. This commentary goes over some limitations in their preliminary analysis, a possible mechanism to explain the phenomenon, and a means by which other i...
Guardado en:
| Publicado en: | Clin Cancer Res |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7372951/ https://ncbi.nlm.nih.gov/pubmed/28258060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2926 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|